Handling the COVID-19 pandemic in the oncological setting

Affiliations

¹ Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona 08908, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. Electronic address: amussetti@iconcologia.net.
² Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona 08908, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
³ Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), Instituto de Salud Carlos III, Madrid, Spain.
⁴ Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
⁵ Intensive Care Medicine, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
⁶ Department of Clinical Oncology and Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Onco-Haematology, University of Milan, Milan, Italy.

Comment

Alberto Mussetti et al. Lancet Haematol. 2020 May.

. 2020 May;7(5):e365-e366.

doi: 10.1016/S2352-3026(20)30108-3. Epub 2020 Apr 1.

¹ Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona 08908, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. Electronic address: amussetti@iconcologia.net.
² Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona 08908, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
³ Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), Instituto de Salud Carlos III, Madrid, Spain.
⁴ Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
⁵ Intensive Care Medicine, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
⁶ Department of Clinical Oncology and Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Onco-Haematology, University of Milan, Milan, Italy.

No abstract available

Comment on

COVID-19 and Italy: what next?
Remuzzi A, Remuzzi G. Remuzzi A, et al. Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178769 Free PMC article. Review.

1. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 doi: 10.1016/S0140-6736(20)30627-9. published online March 12. - DOI - PMC - PubMed
1. Jones DS. History in a crisis—lessons for Covid-19. N Eng J Med. 2020 doi: 10.1056/NEJMp2004361. published online March 12. - DOI - PubMed
1. Wu Z, McCoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020 doi: 10.1001/jama.2020.2648. published online Feb 24. - DOI - PubMed
1. Liang W, Guan W, Chen R. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 doi: 10.1016/S1470-2045(20)30096-6. published online Feb 14. - DOI - PMC - PubMed
1. Li R, Pei S, Chen B. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Science. 2020 doi: 10.1126/science.abb3221. published online March 16. - DOI - PMC - PubMed